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ABSTRACT 1 
It has been reported that both OLR1 and PCSK9 genes are related to various vascular 2 
diseases such as atherosclerosis, cardiovascular disease, peripheral artery disease and 3 
stroke, in particular ischemic stroke. The prevalence of PCSK9 rs505151 and OLR1 4 
rs11053646 variants in ischemic stroke were 0.005 and 0.116, respectively. However, to 5 
date, association between OLR1 rs11053646 and PCSK9 rs505151 polymorphisms and 6 
the risk of ischemic stroke remains unclear and inconclusive. Therefore, this first meta-7 
analysis was carried out to clarify the presumed influence of genetic polymorphisms on 8 
ischemic stroke, by analyzing the complete coverage of all relevant studies. All eligible 9 
case-control and cohort studies that met the search term were retrieved in multiple 10 
scientific databases. Data of interest such as demographic data and genotyping methods 11 
were extracted from each study, and the meta-analysis was performed using RevMan 5.3 12 
and Metafor R 3.2.1. The pooled odd ratios (ORs) and 95% confidence intervals (CIs) 13 
were calculated using both fixed- and random-effect models. A total of seven case-control 14 
studies encompassing 1897 ischemic stroke cases and 2119 healthy controls were 15 
critically evaluated. Pooled results from the genetic models indicated that OLR1 16 
rs11053646 dominant (OR=1.33. 95%CI:1.11-1.58) and co-dominant models (OR=1.24, 17 
95%CI:1.02-1.51) were significantly associated with ischemic stroke. For PCSK9 18 
rs505151 polymorphism, the OR of co-dominant model (OR=1.36, 95%CI:1.01-1.58) was 19 
found to be higher among ischemic stroke patients. In conclusion, the current meta-20 
analysis highlighted that variant allele of OLR1 rs11053646 G>C and PCSK9 rs505151 21 
A>G may contribute to the susceptibility risk of ischemic stroke. 22 
 23 
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 4 
Introduction 5 
Ischemic stroke is a heterogeneous group of neurovascular diseases and contributes to 6 
major morbidity and mortality in both developed and developing countries [1]. The major 7 
risk factors for ischemic stroke such as obesity, diabetes mellitus, hypertension, 8 
hypercholesterolemia, dyslipidemia and atherosclerosis are well established [2]. 9 
Nevertheless, the mechanism of ischemic stroke has not been fully elucidated and may 10 
involve a complex interplay between environmental and genetic factors, such as 11 
polymorphic variants of the genes that regulate cholesterol and lipid biosynthesis or 12 
degradation [2]. Emerging lines of evidence revealed that lectin-like oxidized-low density 13 
lipoprotein receptor-1 (LOX-1) and proprotein convertase subtilisin/kexin 9 (PCSK9) play 14 
critical roles in hyperlipidemia and atherogenesis development, that ultimately leads to 15 
ischemic stroke [3,4]. 16 
 17 
LOX-1 is one of the major scavenger receptor for oxidized low density lipoprotein (ox-18 
LDL), which encoded by human OLR1 gene. This receptor protein mediates the 19 
recognition, internalization and degradation of ox-LDL. It is known that ox-LDL plays an 20 
important role during atherogenesis, by inducing vascular endothelial cell activation and 21 
dysfunction, results in pro-inflammatory responses, oxidative stress, necrosis and 22 
apoptosis [5]. Endothelial cells apoptosis leads to an increased vascular permeability to 23 
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cells and lipids, smooth muscle cell proliferation, increased coagulation and lipid 1 
accumulation, thus contributes to the development of atherosclerosis [6]. It is suspected 2 
that LOX-1 upregulation may halt and reverse the atherosclerotic lesions, through the 3 
binding, endocytosis, and proteolytic degradation of oxLDL [3,6].  4 
 5 
The OLR1 gene consists of six exons and five introns that spans over 7-kb, which located 6 
on chromosome 12p13.1-p12.3. Several single nucleotide polymorphisms (SNPs) in the 7 
OLR1 gene have been identified, including a c.501G>C transversion on exon 4, which 8 
results in an amino acidic substitution from lysine to asparagine at position 167 9 
(p.K167N). This was found to decrease binding and internalization of ox-LDL [7] and has 10 
been associated with hypertension, myocardial infarction and carotid atherosclerosis [8-11 
10]. More importantly, this SNP is statistically linked to the risk of ischemic stroke, but the 12 
discrepancies still exist among different populations [11-14].  13 
 14 
PCSK9 was formerly known as neural apoptosis-regulated convertase 1 and 15 
characterized as the ninth member of the subtilisin family of kexin-like proconvertases. 16 
PCSK9 plays an essential role in the proteolytic maturation of several secretory proteins 17 
such as neuropeptides, growth factors, cytokines and pro-hormones [15]. The PCSK9 18 
plays an important role in modulating the plasma levels of low density lipoprotein 19 
cholesterol (LDL-C) through a post-transcriptional mechanism. PCSK9 binds to low 20 
density lipoprotein receptor (LDLR) and disrupts its endocytic recycling or directs it for 21 
lysosomal degradation [16,17]. Therefore, PCSK9 activation can downregulate LDLR 22 
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expression and inhibit the uptake of LDL-C, which in turns leading to 1 
hypercholesterolemia and ischemic stroke event [4,18].  2 
 3 
The PCSK9 gene is located on chromosome 1p32.3 and is 22-kb in length. It comprises 4 
of 12 exons and 11 introns, which encodes for 692 amino acid glycoprotein. Previous 5 
studies have investigated the relationship of PCSK9 SNPs and their changes in 6 
circulating LDL-C levels. A common SNP - 23968A>G (rs505151) in exon 12, results in 7 
an amino acid substitution from glutamate to glycine at position 670 (p.E670G), is 8 
potentially associated with the altered enzyme activity of PCSK9 [19]. Moreover, this SNP 9 
has been reported to be associated with the risk of ischemic stroke, but the positive 10 
significance towards ischemic stroke event needs to be confirmed [20-22].  11 
 12 
Both OLR1 and PCSK9 are positively linked, where the inhibition of PCSK9 can suppress 13 
the development of atherosclerosis by disrupting LOX-1 expression [23]. Thus far, no 14 
meta-analysis has yet been conducted to investigate the relationship between OLR1 15 
rs11053646 and PCSK9 rs505151 polymorphisms and ischemic stroke. Therefore, we 16 
undertook the current meta-analysis from all eligible case-control studies and performed 17 
a critical review on these published articles, for the purpose of providing the highest level 18 
of evidence on their risk significance. 19 
 20 
Results 21 
Studies selection and characteristics  22 
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With regard to OLR1 rs11053646 and PCSK9 rs505151 polymorphisms, 84 and 176 1 
studies were identified from the initial search (Figure 1). Of these, six articles and one 2 
thesis were found to be related to the association between the studied polymorphisms 3 
and the risk of ischemic stroke. As for OLR1 rs11053646, one study was excluded due to 4 
insufficient information while another study was reporting on polymorphism other than our 5 
interest (Figure 1). For PCSK9 rs505151, three studies were excluded due to (i) multiple 6 
studies from the same author (n=1), (ii) insufficient information (n=1), and (iii) study that 7 
reporting on polymorphism other than our interest (n=1). No additional eligible article was 8 
found despite performing the extensive manual search on the references cited in the 9 
eligible publications and review articles. Therefore, a total of four (OLR1 rs11053646) and 10 
three articles (PCSK9 rs505151) encompassing 1138 and 759 cases as well as 1213 and 11 
906 controls that met the inclusion criteria were included in the final meta-analysis model 12 
(Figure 1). The detailed characteristics of all the selected studies were presented in Table 13 
1. Meanwhile, the distribution of allele and genotype for each individual study were 14 
demonstrated in Table 2. 15 
 16 
Quantitative synthesis of data 17 
Since heterogeneity has been observed in the overall comparison, random-effect models 18 
were applied for all of the forest plots (Figure 2a-c), except for the OLR1 rs11053646 19 
dominant and co-domiant models (Figure 2d-e). Ironically, the majority of genetic models 20 
for PCSK9 rs505151 were fixed-effect models, except for its recessive genetic model 21 
(Figure 3a-e). Nevertheless, the dominant model of OLR1 rs11053646 was significantly 22 
increased the risks towards ischemic stroke with odd ratio (OR) 1.33 (95%CI:1.11-1.58, 23 
7 
 
p=0.002). Interestingly, both of the co-dominant models for OLR1 rs11053646 and 1 
PCSK9 rs505151 demonstrated similar odds towards ischemic stroke (OR=1.24, 2 
95%CI:1.02-1.51, p=0.03; OR=1.36, 95%CI:1.01-1.85, p<0.05, respectively). Although it 3 
is not statistically significant, the GG genotype carriers of PCSK9 rs505151 had a higher 4 
risk of ischemic stroke as compared to the wild-type carriers (OR=3.56, 95%CI:0.96-5 
13.20, p=0.06). 6 
 7 
Heterogeneity and publication bias 8 
The significance of inter-study heterogeneity in the overall comparison models is 9 
summarized as Phet<0.10 and I2>50% (Table 3). Meanwhile, the potential publication bias 10 
was analyzed by performing both of the Begg's and Egger's tests. The shapes of funnel 11 
plots were relatively symmetry, except for the PCSK9 rs505151 co-dominant model 12 
(Figure 5) and OLR1 rs11053646 homozygous, heterozygous and recessive models 13 
(Figure 4). However, the results from Egger’s test showed no significance of publication 14 
bias for all the tested genetic models (p>0.05), suggesting that publication bias is not 15 
existed in this meta-analysis model. In particular, a non-significant p-value of 0.52 was 16 
observed for the co-dominant model of PCSK9 rs505151. Likewise, no significant 17 
evidence of publication bias were identified under OLR1 rs11053646 homozygous 18 
(p=0.31) and recessive (p=0.37) models, except for the heterozygous model (p=0.002). 19 
 20 
Discussion 21 
To the best of our knowledge, this is the first meta-analysis that comprehensively 22 
assessed the association between OLR1 rs11053646 and PCSK9 rs505151 23 
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polymorphisms with the risk of ischemic stroke. In this study, a total of seven eligible 1 
articles comprising 1897 stroke cases and 2119 healthy controls were included. The 2 
present meta-analysis covered all the publications indexed in the major databases such 3 
as PubMed, Scopus and Web of Science, as well as other databases from China, Hong 4 
Kong, India, Japan, Korea, Malaysia, Russia and Latin America. The positive association 5 
between the allelic variant of the studied genes and increased ischemic stroke risks 6 
represent the major findings of this meta-analysis. Present study has extended our 7 
previous knowledge on the participation of a large number of candidate genes in the 8 
development of ischemic stroke, particularly the genes involved in the coagulation, 9 
homocysteine and lipid signaling pathways [2]. 10 
 11 
The clinical impact of OLR1 in the pathogenesis of atherosclerosis and ischemic stroke 12 
has been investigated [3]. A higher LOX index was reported to be positively associated 13 
with ischemic stroke risk [24]. The SNP rs11053646 has been reported to be associated 14 
with the precursors of ischemic stroke such as carotid atherosclerotic plaque, intima-15 
media thickness and left ventricular hypertrophy [25-27]. Functional screening and in vitro 16 
analysis has demonstrated that amino acids substitution of p.K167N (c.501G>C) may 17 
reduce the binding affinity of the OLR1 receptor and reduce the LOX-1 expression [7]. In 18 
human subjects, the CC variant possesses a lower binding affinity towards ox-LDL and 19 
reduced its mRNA expression, which lead to an increased inflammation and affect the 20 
atherogenic process in the carotid artery [28]. In contrast, a 11-year follow-up study 21 
reported that plasma soluble LOX-1 levels were elevated in the CC genotype carriers as 22 
compared to GG genotype among Japanese [24]. In this meta-analysis, OLR1 23 
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rs11053646 C allele is associated with ischemic stroke in the dominant model and/or in 1 
the recessive model. Consistent with this phenomenon, Liu and colleagues [14] reported 2 
that the CC + GC genotype and C allele of this SNP increased the risks of ischemic stroke 3 
in Chinese population (OR=1.51, p<0.001; OR=1.32, p=0.04, respectively). Similarly, 4 
Zhang et al [13] found that C allele (OR=1.52, p<0.001) and CC genotype (OR=2.08, 5 
p=0.001) were significantly higher among Chinese patients with ischemic stroke. 6 
However, other studies have shown a lack of association between this SNP and ischemic 7 
stroke [11,12]. Hattori et al [11] suggested the CC + GC genotype and C allele were less 8 
likely to be associated with ischemic stroke (OR=1.14, p=0.48; OR=0.98, p=0.91, 9 
respectively). Likewise, a relatively small number of study [12] has indicated the higher 10 
frequencies of CC genotype (OR=1.33) and C allele (OR=1.09) among ischemic stroke 11 
patients, but the differences with controls were not statistically significant (p=0.66 and 12 
p=0.63). Hence, the presence of genetic heterogeneity and small sample size could 13 
possibly explain the divergent results of these studies.  14 
 15 
Increasing evidence has indicated the critical roles of PCSK9 in the risk of 16 
hypercholesterolemia and ischemic stroke [4]. Recently, PCSK9 inhibitor shows 17 
promising results for the treatment of familial hypercholesterolemia and significantly 18 
reduced the LDL-C levels [29-31]. It is generally well accepted that genetic 19 
polymorphisms in PCSK9 gene can contribute to the variable expression and affect the 20 
enzyme activity of PCSK9. Nevertheless, the association between p.E670G and LDL-C 21 
still remains controversial. Some studies [21,32-34] have reported positive associations 22 
between G allele and increased levels of LDL-C, whereas other study [35] has shown 23 
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contrary finding. Moreover, PCSK9 670 GG variant is associated with higher LDL-C levels 1 
and increased intima-media thickness progression, in the presence of ApoE4 allele [34]. 2 
In contrast, several studies suggested that LDL-C levels are not mediated by this SNP 3 
[36-38]. With regards to the association of disease, this meta-analysis revealed that the 4 
co-dominant model of PCSK9 rs505151 is associated with ischemic stroke, where the 5 
distribution of G allele is higher among ischemic stroke patients. Among the included 6 
studies, Abboud and colleagues [20] first demonstrated a potential association of this 7 
SNP with ischemic stroke, especially the large-vessel atherosclerosis stroke. The odd 8 
ratios of G allele and AG + GG genotype were higher among Belgian ischemic stroke 9 
subjects (OR=2.10, p=0.047; OR=2.01, p=0.045 respectively). This observation is further 10 
supported by a Tunisian case-control study, where the incidence of G alleles (OR=1.77, 11 
p=0.032) tends to be higher towards ischemic stroke risk [21]. Interestingly, patients with 12 
AG and AA genotypes have their LDL-C levels twice as high as the normal control 13 
subjects, which indicated the association between this SNP and the risk of ischemic 14 
stroke is mediated by increased levels of LDL-C. However, the odd ratios of G allele were 15 
divergently reported among Hans (0.73) and Uygur (0.63) populations [22].Their study 16 
suggested that there is no significant association between rs505151 and ischemic stroke, 17 
but the LDL-C levels have not been determined [22]. It is noteworthy that the true effect 18 
of this SNP could be masked by other genes or environmental factors. 19 
 20 
A pertinent source of bias in the meta-analysis is that the source of selected study may 21 
be skewed due to the tendency of journals in selectively publishing studies with positive 22 
findings. Begg’s funnel plots demonstrated the existence of publication bias in different 23 
11 
 
genetic models of OLR1 rs11053646 and PCSK9 rs505151. However, the non-significant 1 
P-value of Egger’s test (p>0.05) indicated that the overall pooled results are unbiased, 2 
except for the OLR1 rs11053646 heterozygous model. Therefore, the results of this model 3 
shall be interpreted with caution. The observed heterogeneity may be attributed by the 4 
different ethnicities, sample size, study design, genotyping methods, and other 5 
environmental factors. Moreover, population heterogeneity may be derived from the 6 
genetic diversity of individual studies, i.e. genetic diversity may still exist even though the 7 
studied subjects are derived from the same populations, ethnicity, countries and districts. 8 
 9 
However, there are several limitations in the current meta-analysis. For instance, we did 10 
not perform stratification analysis according to ischemic stroke subtypes since TOAST 11 
classification was not been reported in any of the eligible studies. In addition, the 12 
subgroup analysis has not been carried out in this meta-analysis. The population data of 13 
PCSK9 rs505151 are limited for the subgroup analysis, since only a single Asian 14 
population was presented in this meta-analysis. Despite these limitations, our meta-15 
analysis covered the most available association case-control studies, involving the 16 
hospital- and population-based studies. Furthermore, the present study has provided a 17 
better understanding on the association between the studied SNPs and the risk of 18 
ischemic stroke for the first time. 19 
 20 
In conclusion, the current meta-analysis suggested that the variant alleles of OLR1 21 
rs11053646 and PCSK9 rs505151 may confer an increased risk of ischemic stroke. 22 
Therefore, these SNPs maybe used as the genetic biomarker which help to reduce the 23 
12 
 
burden of ischemic stroke, and serving as the potential targets for diagnostic and 1 
therapeutic implications. The foremost, this meta-analysis served a pertinent purpose for 2 
shaping the future of translational research in ischemic stroke. Further investigations with 3 
larger number of samples from more countries are needed, in order to facilitate the 4 
translation of genetic biomarkers into clinical practice.  5 
 6 
Methods 7 
Search strategy 8 
This meta-analysis followed the Cochrane Collaboration definition and PRISMA 2009 9 
guidelines for meta-analysis and systematic review. We performed a comprehensive 10 
literature search throughout PubMed, Scopus, Web of Science, Google scholar, WHO 11 
Global Health Library, VHL, Jstage, KoreaMed, Korean Science Citation Index, 12 
POPLINE, New York Academy of Medicine Grey Literature Report, Indian Citation Index, 13 
System for Information on Grey Literature in Europe, IMSEAR, MJM, Mycite, WPRIM and 14 
CNKI to retrieve the genetic association studies of ischemic stroke. The medical subject 15 
heading and keywords terms “lectin-like oxidized LDL receptor-1”, “LOX-1”, “OLR1”, 16 
“proprotein convertase subtilisin/kexin type 9”, “PCSK9”, “neural apoptosis-regulated 17 
convertase 1”, “NARC1”,  “ischemic stroke”, “cerebrovascular disease”, “cerebrovascular 18 
accident”, “brain infarction”, “brain ischemia”,  “cerebral ischemia”, polymorphism”, 19 
“variant”, “gene mutation”, “single nucleotide polymorphism (SNP)”, “gene variation” and 20 
the related Chinese characters were used as the criteria for searching. There was no 21 
limitation in language, where articles written in English, Japanese, Korean, Spanish, 22 
13 
 
Russian or Chinese were retrieved. In addition, the time period for literature searching 1 
was from the first available article until July 2015.  2 
 3 
Study selection and data abstraction 4 
The inclusion criteria for the gene association studies in the final meta-analysis were as 5 
follows: (i) case-control and/or cohort studies; (ii) contained SNP genotype data; and (iii) 6 
adequate data for the calculation of odds ratios (ORs) and 95% confidence intervals (CIs).  7 
 8 
Data abstraction was performed independently by two authors (A.A. and L.K.W.). This 9 
meta-analysis was conducted when the data of three unduplicated studies are available. 10 
The following information from each study was summarized: (i) first author; (ii) publication 11 
year; (iii) province of study population; (iv) ethnicity; (v) number of cases and controls; (vi) 12 
mean age and sex ratio; and (vii) genotyping method. 13 
 14 
Statistical analysis 15 
The genotypic distributions for studied polymorphisms were compared against the 16 
controls for any possible deviations from the Hardy-Weinberg equilibrium. Crude OR and 17 
95% confident interval (CIs) were calculated to test the strength of associations between 18 
studied polymorphisms and ischemic stroke. The significance of the pooled ORs was 19 
determined by Z test for polymorphisms under different genetic models (homozygous, 20 
heterozygous, recessive, dominant and co-dominant) for OLR1 rs11053646 and PCSK9 21 
rs505151. The heterogeneity for all the included studies was evaluated using Cochran’s 22 
Q test and I2 statistics. The random-effects model was chosen when significant 23 
14 
 
heterogeneous exist (Pheterogeneity < 0.05, I2 > 50%); otherwise, fixed-effects model would 1 
be adopted. Potential publication bias was tested with Begg’s funnel plot and Egger’s 2 
regression test. The statistical tests were performed using the Review manager version 3 
5.3 and Metafor package in R version 3.2.1 [39]. All statistics were two-sided and p<0.05 4 
was considered statistically significant. 5 
 6 
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Table 1: Main characteristic of the studies included in the current meta-analysis 1 
Author Year Country Ethnicity Total no. of Mean age Sex (M/F) Control Origin Genotyping method  
Case Control Case Control Case Control   
Abboud, 
S 
2007 Belgium Caucasians 237 326 53.5 70.3 2.0 2.0 Population-
based 
TaqMan SNP 
genotyping assay 
Han, Da 2014 China Asians 250 199 63.6 ± 11.3 62.4 ± 11.7 2.5 1.1 Hospital-based Single-base terminal 
extension 
Han, Db 2014 China Caucasians 158 149 59.4 ± 12.0 61.2 ± 11.5 1.6 1.2 Hospital-based Single-base terminal 
extension 
Hattori, 
H 
2006 Japan Asians 235 274 58.3 ± 7.8 59.1 ± 3.4 3.5 2.5 Hospital-based Single-nucleotide 
primer extension 
Li, D 2009 China Asians 213 176 60.0 ± 13.8 59.0 ± 11.4 1.2 1.2 Hospital-based Restriction fragment 
length polymorphism 
Liu, X 2014 China Asians 386 386 62.1 ± 9.9 61.9 ± 9.8 2.2 2.2 Hospital-based Ligation detection 
reaction 
Slimani, 
A 
2014 Tunisia Caucasians 114 232 66 (54.5-
76.5) 
49.0 (45.0-
55.0) 
1.4 2.9 Hospital-based Restriction fragment 
length polymorphism 
Zhang, J 2013 China Asians 304 377 61.2 ± 7.1 61.1 ± 6.9 1.5 1.6 Population-
based 
Restriction fragment 
length polymorphism 
a and b are from the same study, Han D et al (2014). 2 
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Table 2: The distribution of alleles and genotypes of OLR1 rs11053646 and PCSK9 rs505151polymorphisms in the current 1 
meta-analysis 2 
Studied 
Polymorphisms 
Author Year Sample size Case Control       HWE 
Case Control W H V D M W H V D M p value 
OLR1 
rs11053646 
Hattori, H 2006 235 274 143 85 7 371 99 175 81 18 431 117 0.05 
Li, D 2009 213 176 131 77 5 339 87 112 61 3 285 67 0.10 
Liu, X 2014 386 386 239 135 12 613 159 274 97 15 645 127 0.09 
Zhang, J 2013 304 377 61 126 117 248 360 103 179 95 385 369 0.33 
PCSK9 
rs505151 
Abboud, S 2007 237 326 218 18 1 454 20 312 14 0 638 14 0.69 
Han, Da 2014 250 199 219 30 1 468 32 179 20 0 378 20 0.46 
Han, Db 2014 158 149 146 11 1 303 13 131 17 1 279 19 0.59 
Slimani, A 2014 114 232 90 20 4 200 28 199 32 1 430 34 0.81 
 3 
HWE: Hardy-Weinberg Equilibrium; W: wild type; H: heterozygous; V: variant; D: dominant allele frequency; M: minor 4 
allele frequency. 5 
 6 
 7 
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Table 3: Meta-analysis of the association between OLR1 rs11053646 and PCSK9 rs505151 with ischemic stroke risk. 1 
Variables  
 
No. 
of 
study 
Sample size 
(cases/controls) 
Homozygous Heterozygous Recessive Dominant  Co-dominant 
OR 
(95% 
CI)  
P P het I2 
(%) 
OR 
(95% 
CI)  
P P 
het 
I2 
(%) 
OR 
(95% 
CI)  
P P het I2 
(%) 
OR 
(95% 
CI)  
P P 
het 
I2 
(%) 
OR 
(95% 
CI)  
P P 
het 
I2 
(%) 
OLR1 
rs11053646 
G>C 
4 1138/1213 CC vs. GG GC vs. GG CC vs. (GG +. GC) (GC + CC) vs. GG C vs. G 
  1.00 
(0.47-
2.12) 
1.00 0.009 74 1.16 
(0.83-
1.62) 
0.39 0.01 74 1.00 
(0.47-
2.11) 
1.00 0.009 74 1.33 
(1.11-
1.58) 
0.002 0.45 0 1.24 
(1.02-
1.51) 
0.003 0.11 51 
PCSK9 
rs505151 
A>G 
3 759/906 GG vs. AA AG vs. AA GG vs. (AA + AG) (AG + GG) vs. AA G vs. A 
  3.56 
(0.96-
13.20) 
0.06 0.68 0 1.19 
(0.86-
1.66) 
0.30 0.20 35 1.61 
(0.04-
67.16) 
0.06 0.68 0 1.29 
(0.94-
1.79) 
0.12 0.13 47 1.36 
(1.01-
1.85) 
0.05 0.09 54 
P, p-value for Z test; P het, p-value for Cochrane’s Q test2 
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Figures 1 
Figure 1: Flow chart of the study selection process for OLR1 rs11053646 (a) and PCSK9 2 
rs505151 (b). 3 
 4 
Figure 2: Forest plot of odds ratios for the association between OLR1 rs11053646 and 5 
ischemic stroke risk. a: under homozygous model (CC vs GG); b: under heterogeneous 6 
model (GC vs GG); c: under recessive model (GG + GC vs CC); d: under dominant model 7 
(GC + CC vs GG); e: under co-dominant model (C vs G). 8 
 9 
Figure 3: Forest plot of odds ratios for the association between PCSK9 rs505151 and 10 
ischemic stroke risk. a: under homozygous model (GG vs AA); b: under heterogeneous 11 
model (AG vs AA); c: under recessive model (AA + AG vs GG); d: under dominant model 12 
(AG + GG vs AA); e: under co-dominant model (G vs A). 13 
 14 
Figure 4: Funnel plot of publication bias for the association between OLR1 rs11053646 15 
and ischemic stroke risk. a: under homozygous model (CC vs GG); b: under 16 
heterogeneous model (GC vs GG); c: under recessive model (GG + GC vs CC); d: under 17 
dominant model (GC + CC vs GG); e: under co-dominant model (C vs G). 18 
 19 
Figure 5: Funnel plot of publication bias for the association between PCSK9 rs505151 20 
and ischemic stroke risk. a: under homozygous model (GG vs AA); b: under 21 
heterogeneous model (AG vs AA); c: under recessive model (AA + AG vs GG); d: under 22 
dominant model (AG + GG vs AA); e: under co-dominant model (G vs A). 23 
 24 
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